Value of Renal Vascular Doppler Sonography in Management of Decompensated Heart Failure

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02372292

Enrollment

Registered

2015-02-26

Start date

2013-02-28

Completion date

2015-06-30

Last updated

2015-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cardiorenal Syndrome

Keywords

cardiorenal syndrome, decompensated heart failure, renal resistivity index, venous impedance index, kidney failure

Brief summary

Although the traditional determinant of renal dysfunction in heart failure was suggested as decreased cardiac output and renal hypo perfusion, recent studies have demonstrated the association of persistent systemic venous congestion and kidney dysfunction. Relief of the congestion has demonstrated to improve renal functions in decompensated heart failure. The current trial was set up to investigate the changes of renal venous impedance and renal arteriolar resistivity indices with diuretic therapy, in patients with congestive renal failure. The investigators asked whether measurement of renal venous impedance index or renal arteriolar resistivity index can guide the practice of diuretic therapy.

Interventions

DRUGintravenous furosemide

Decongestant therapy for decompensated heart failure which may be administrated as intravenous bolus or infusion

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

DIAGNOSTIC

Masking

SINGLE (Subject)

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Decompensated heart failure * Elevated serum creatinine levels on admission

Exclusion criteria

* Atrial fibrillation * Obstructive uropathy * Patients with ascites * Patients who exposed the potential nephrotoxic drugs in the previous week (metformin, antibiotics, chemotherapeutics, iodinated contrast agents and non-steroidal anti-inflammatory agents) * Patients who needed positive inotropic agents

Design outcomes

Primary

Measure	Time frame	Description
Alterations in the renal arterial resistivity index	during hospitalization, an expected average of 4 weeks.	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.

Secondary

Measure	Time frame	Description
Alterations in the renal venous impedance index	during hospitalization, an expected average of 4 weeks.	Participants will be followed for the duration of hospital stay, an expected average of 4 weeks.

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026